| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Autologous hematopoietic cell transplantation for AML in first remission – An abandoned practice or promising approach?
|
Yeshurun, Moshe
|
|
2019
|
56 |
2 |
p. 139-146
|
artikel
|
| 2 |
Can we predict responsiveness to hypomethylating agents in AML?
|
Stomper, Julia
|
|
2019
|
56 |
2 |
p. 118-124
|
artikel
|
| 3 |
Curative strategies in APL
|
Iland, Harry J.
|
|
2019
|
56 |
2 |
p. 131-138
|
artikel
|
| 4 |
Exciting Times in Acute Myeloid Leukemia
|
Tallman, Martin S.
|
|
2019
|
56 |
2 |
p. 83
|
artikel
|
| 5 |
Genetic and epigenetic determinants of AML pathogenesis
|
Cai, Sheng F.
|
|
2019
|
56 |
2 |
p. 84-89
|
artikel
|
| 6 |
Maintenance therapy in acute myeloid leukemia: What is the future?
|
McMahon, Christine M.
|
|
2019
|
56 |
2 |
p. 102-109
|
artikel
|
| 7 |
New approaches in allogenic transplantation in AML ☆
|
Pei, Xuying
|
|
2019
|
56 |
2 |
p. 147-154
|
artikel
|
| 8 |
outside front cover, PMS 8883 metallic AND 4/C
|
|
|
2019
|
56 |
2 |
p. CO1
|
artikel
|
| 9 |
Risks and benefits in a personalized application of allogeneic transplantation in patients with AML in first CR
|
Versluis, Jurjen
|
|
2019
|
56 |
2 |
p. 164-170
|
artikel
|
| 10 |
Shifting paradigms in the treatment of older adults with AML
|
LeBlanc, Thomas W.
|
|
2019
|
56 |
2 |
p. 110-117
|
artikel
|
| 11 |
The emerging role of measurable residual disease detection in AML in morphologic remission
|
Buccisano, F.
|
|
2019
|
56 |
2 |
p. 125-130
|
artikel
|
| 12 |
The 2016 WHO classification of acute myeloid leukemia: What the practicing clinician needs to know
|
Arber, Daniel A.
|
|
2019
|
56 |
2 |
p. 90-95
|
artikel
|
| 13 |
What's new in consolidation therapy in AML?
|
Schlenk, Richard F.
|
|
2019
|
56 |
2 |
p. 96-101
|
artikel
|
| 14 |
Will CAR T cell therapy have a role in AML? Promises and pitfalls
|
Cummins, Katherine D.
|
|
2019
|
56 |
2 |
p. 155-163
|
artikel
|
Tijdschrift beschrijving